These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32977825)

  • 21. PITUITARY PARS INTERMEDIA DYSFUNCTION (EQUINE CUSHING'S DISEASE) IN NONDOMESTIC EQUIDS AT MARWELL WILDLIFE: A CASE SERIES. ONE CHAPMAN'S ZEBRA ( EQUUS QUAGGA CHAPMANI) AND FIVE PRZEWALSKI's HORSES ( EQUUS FERUS PRZEWALSKII).
    Shotton JCR; Justice WSM; Salguero FJ; Stevens A; Bacci B
    J Zoo Wildl Med; 2018 Jun; 49(2):404-411. PubMed ID: 29900762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy.
    Fortin JS; Hetak AA; Duggan KE; Burglass CM; Penticoff HB; Schott HC
    Sci Rep; 2021 Aug; 11(1):16036. PubMed ID: 34362943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
    Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
    Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI; Litchfield E; Heller J; Hughes KJ
    Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of advanced age and pituitary pars intermedia dysfunction on components of the acute phase reaction in horses.
    Zak A; Siwinska N; Elzinga S; Barker VD; Stefaniak T; Schanbacher BJ; Place NJ; Niedzwiedz A; Adams AA
    Domest Anim Endocrinol; 2020 Jul; 72():106476. PubMed ID: 32380311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships of inflamm-aging with circulating nutrient levels, body composition, age, and pituitary pars intermedia dysfunction in a senior horse population.
    Siard-Altman MH; Harris PA; Moffett-Krotky AD; Ireland JL; Betancourt A; Barker VD; McMurry KE; Reedy SE; Adams AA
    Vet Immunol Immunopathol; 2020 Mar; 221():110013. PubMed ID: 32058159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lumbar vertebral bone density is decreased in horses with pituitary pars intermedia dysfunction.
    Colbath AC; Fortin JS; Burglass CM; Panek C; Vergara-Hernandez FB; Johnson TN; Robison CA; Logan AA; Nelson NA; Nielsen BD; Schott HC
    Equine Vet J; 2024 Mar; 56(2):368-376. PubMed ID: 38151767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perianesthetic development of diaphragmatic hernia in a horse with equine pituitary pars intermedia dysfunction (PPID).
    Shepard MK; Lee WL; Eggleston RB
    Can Vet J; 2015 Jan; 56(1):48-52. PubMed ID: 25565714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pituitary pars intermedia dysfunction: equine Cushing's disease.
    Schott HC
    Vet Clin North Am Equine Pract; 2002 Aug; 18(2):237-70. PubMed ID: 15635907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutics for Equine Endocrine Disorders.
    Durham AE
    Vet Clin North Am Equine Pract; 2017 Apr; 33(1):127-139. PubMed ID: 28190613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful medical treatment of an Aspergillus terreus mycetoma of the nostril/lip in a 16-year-old Fjord pony gelding with pituitary pars intermedia dysfunction.
    Randleff-Rasmussen PK; Mosca M; Knoerr F; Pin D; Desjardins I
    Vet Dermatol; 2017 Dec; 28(6):629-e155. PubMed ID: 28736852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
    McFarlane D; Cribb AE
    Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strongyle egg shedding and egg reappearance periods in horses with pituitary pars intermedia dysfunction.
    Horner A; Bamford NJ; Stear MJ; Piedrafita D; Jabbar A; Hughes KJ; El-Hage CM; Preston S
    Vet Parasitol; 2024 Jun; 328():110176. PubMed ID: 38603926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
    Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.
    Miller C; Utter ML; Beech J
    Am J Vet Res; 2013 Jul; 74(7):1030-5. PubMed ID: 23802675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary pars intermedia dysfunction does not necessarily impair insulin sensitivity in old horses.
    Mastro LM; Adams AA; Urschel KL
    Domest Anim Endocrinol; 2015 Jan; 50():14-25. PubMed ID: 25240230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-related Qualitative Histological and Quantitative Stereological Changes in the Equine Pituitary.
    Leitenbacher J; Herbach N
    J Comp Pathol; 2016; 154(2-3):215-24. PubMed ID: 26810844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.
    McFarlane D
    Ageing Res Rev; 2007 May; 6(1):54-63. PubMed ID: 17374512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.